| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/RMV.1717 |
| P698 | PubMed publication ID | 22570186 |
| P50 | author | Manuel Rosa-Calatrava | Q56432987 |
| Bruno Lina | Q61117468 | ||
| Guy Boivin | Q90829727 | ||
| P2093 | author name string | Jean-Christophe Le Bayon | |
| P2860 | cites work | Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. | Q51812238 |
| Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. | Q54420528 | ||
| A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines | Q56689869 | ||
| Progress in respiratory virus vaccine development | Q56894869 | ||
| Human metapneumovirus glycoprotein G inhibits innate immune responses | Q21090523 | ||
| Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion | Q24538786 | ||
| Bimolecular complementation of paramyxovirus fusion and hemagglutinin-neuraminidase proteins enhances fusion: implications for the mechanism of fusion triggering | Q24645164 | ||
| An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers | Q24684635 | ||
| Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein | Q27658463 | ||
| Structure of the Newcastle disease virus F protein in the post-fusion conformation | Q27661271 | ||
| Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers | Q27667876 | ||
| Identification of nucleolin as a cellular receptor for human respiratory syncytial virus | Q28245563 | ||
| Mortality associated with influenza and respiratory syncytial virus in the United States | Q29615578 | ||
| Progress in respiratory virus vaccine development. | Q30361299 | ||
| Incubation periods of acute respiratory viral infections: a systematic review. | Q30376497 | ||
| Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. | Q30398693 | ||
| Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates | Q33604189 | ||
| Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees | Q33605207 | ||
| Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys | Q33748766 | ||
| Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. | Q33807998 | ||
| Assembly and biological and immunological properties of Newcastle disease virus-like particles | Q33826688 | ||
| Hemagglutinin-neuraminidase-independent fusion activity of simian virus 5 fusion (F) protein: difference in conformation between fusogenic and nonfusogenic F proteins on the cell surface | Q33845134 | ||
| Population-based incidence of human metapneumovirus infection among hospitalized children | Q33862733 | ||
| Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice | Q45386439 | ||
| The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans | Q45420643 | ||
| Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation | Q45421033 | ||
| Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys | Q45450064 | ||
| Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial | Q45458064 | ||
| Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants | Q45504141 | ||
| Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections | Q45706430 | ||
| Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000 | Q45709956 | ||
| Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease | Q45710733 | ||
| Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine | Q45712258 | ||
| Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants | Q45728723 | ||
| Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants | Q45736044 | ||
| Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome | Q45736390 | ||
| Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy | Q45739555 | ||
| Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines | Q45741570 | ||
| Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection | Q45748032 | ||
| CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection | Q45757956 | ||
| Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus | Q45759631 | ||
| Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. | Q45761513 | ||
| Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus | Q45766924 | ||
| Partial characterization of a Sendai virus replication promoter and the rule of six. | Q45767226 | ||
| Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3. | Q45774616 | ||
| Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein | Q45775644 | ||
| Possible transmission by fomites of respiratory syncytial virus | Q45791372 | ||
| Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation | Q45808569 | ||
| Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine | Q45823297 | ||
| Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis | Q45837485 | ||
| Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. | Q50568964 | ||
| Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. | Q50619591 | ||
| Mode of action of adjuvants: implications for vaccine safety and design. | Q51043479 | ||
| A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus | Q33928650 | ||
| Soluble recombinant human metapneumovirus G protein is immunogenic but not protective | Q33950358 | ||
| Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates | Q33984333 | ||
| Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates | Q34092801 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Progress in the development of human parainfluenza virus vaccines | Q34209872 | ||
| Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo | Q34228628 | ||
| Combined Live Measles, Mumps, and Rubella Virus Vaccines | Q34240333 | ||
| Addition of N-glycans in the stalk of the Newcastle disease virus HN protein blocks its interaction with the F protein and prevents fusion | Q34301817 | ||
| Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector | Q34302198 | ||
| Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease | Q34330690 | ||
| Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children | Q34333040 | ||
| Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins | Q34457791 | ||
| The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response | Q34651391 | ||
| A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice | Q34884984 | ||
| Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years | Q35566601 | ||
| Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats | Q35634929 | ||
| The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription | Q35645905 | ||
| Sendai virus-based RSV vaccine protects African green monkeys from RSV infection | Q35667184 | ||
| Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate | Q35826221 | ||
| Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro | Q35857720 | ||
| Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes | Q35924915 | ||
| Reverse genetics of negative-stranded RNA viruses: a global perspective | Q36053078 | ||
| Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. | Q36088161 | ||
| Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus | Q36422618 | ||
| Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B | Q36453608 | ||
| The structural basis of paramyxovirus invasion | Q36469974 | ||
| A conserved region between the heptad repeats of paramyxovirus fusion proteins is critical for proper F protein folding | Q36851832 | ||
| Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates | Q36898701 | ||
| Low-pH triggering of human metapneumovirus fusion: essential residues and importance in entry | Q37051640 | ||
| Integrin alphavbeta1 promotes infection by human metapneumovirus | Q37068968 | ||
| Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected] | Q37093418 | ||
| Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis | Q37144043 | ||
| Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans | Q37297096 | ||
| Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections | Q37308711 | ||
| Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. | Q37348134 | ||
| The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines | Q37384009 | ||
| Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys | Q37568127 | ||
| Respiratory syncytial virus disease: update on treatment and prevention | Q37822453 | ||
| Local cytokine response upon respiratory syncytial virus infection. | Q37825057 | ||
| Ten years of human metapneumovirus research. | Q37954833 | ||
| Deletion of human metapneumovirus M2-2 increases mutation frequency and attenuates growth in hamsters | Q39123938 | ||
| Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector | Q39593656 | ||
| AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats | Q39615678 | ||
| Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture | Q39684652 | ||
| Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene | Q39732519 | ||
| Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3 | Q39796610 | ||
| Role of retinoic acid inducible gene-I in human metapneumovirus-induced cellular signalling | Q39960512 | ||
| Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity | Q39997643 | ||
| Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus | Q40048609 | ||
| Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract | Q40158643 | ||
| Function of small hydrophobic proteins of paramyxovirus | Q40324541 | ||
| Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates | Q40338559 | ||
| Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses | Q40407821 | ||
| Effectiveness of maternal influenza immunization in mothers and infants | Q40409398 | ||
| Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults | Q40490986 | ||
| A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy | Q40513717 | ||
| Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. | Q40541369 | ||
| Immunopathogenesis of vaccine-enhanced RSV disease. | Q40595357 | ||
| Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy | Q40614352 | ||
| Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro | Q40630466 | ||
| Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo | Q40771213 | ||
| An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 | ||
| The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells | Q41003033 | ||
| Identification of regions on the fusion protein of human parainfluenza virus type 2 which are required for haemagglutinin-neuraminidase proteins to promote cell fusion | Q41064314 | ||
| Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines | Q42070355 | ||
| Low-pH-induced membrane fusion mediated by human metapneumovirus F protein is a rare, strain-dependent phenomenon | Q42148034 | ||
| Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. | Q42428474 | ||
| Virologically confirmed population-based burden of hospitalization caused by respiratory syncytial virus, adenovirus, and parainfluenza viruses in children in Hong Kong. | Q43173863 | ||
| Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy | Q44286818 | ||
| A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys | Q44776054 | ||
| Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children | Q44825036 | ||
| Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques | Q45216908 | ||
| Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection | Q45220298 | ||
| Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. | Q45232426 | ||
| Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children | Q45363218 | ||
| A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease | Q45367066 | ||
| Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children | Q45384017 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | attenuated vaccine | Q1810913 |
| P304 | page(s) | 15-34 | |
| P577 | publication date | 2012-05-08 | |
| P1433 | published in | Reviews in Medical Virology | Q15766137 |
| P1476 | title | Recent developments with live-attenuated recombinant paramyxovirus vaccines | |
| P478 | volume | 23 |
| Q39142106 | Characterization of a key residue for hyperfusogenic phenotype in human parainfluenza virus type 2 (hPIV-2) fusion glycoprotein. |
| Q58774142 | Discovery and genome characterization of three new Jeilongviruses, a lineage of paramyxoviruses characterized by their unique membrane proteins |
| Q38177359 | Epidemiology, etiology, x-ray features, importance of co-infections and clinical features of viral pneumonia in developing countries. |
| Q45323929 | Immunogenicity of recombinant measles vaccine expressing fusion protein of respiratory syncytial virus in cynomolgus monkeys |
| Q38200134 | Medical prevention of recurrent acute otitis media: an updated overview. |
| Q38266413 | RNA-based viral vectors |
| Q37118707 | Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses |
| Q38785894 | Site-specific glycosylation of the Newcastle disease virus haemagglutinin-neuraminidase |
| Q64974108 | Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors. |
Search more.